Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabineZay Yar Oo, Brian Gabrielli|Molecular Oncology|2019Cited by 24